Why the McPherson's (ASX:MCP) share price could charge higher on Tuesday

The McPherson's Ltd (ASX:MCP) share price will be one to watch on Tuesday following an after market update today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The McPherson's Ltd (ASX: MCP) share price will be on watch on Tuesday following the release of a trading update after the market close.

What did McPherson's announce?

This afternoon McPherson's confirmed that sales from its core brands in the Australian market continue to exceed last year's figures.

According to the release, year to date, the company's owned brands, excluding the Dr. LeWinn's brand, have recorded sales growth of 7%.

This has been driven by double digit sales growth from the Manicare, Lady Jayne, and A'kin brands. Furthermore, market share growth has been recorded from 4 out of 6 of its owned brands.

The Dr. LeWinn's brand continues to weigh on the company's performance, though. Like A2 Milk Company Ltd (ASX: A2M), this has been caused by weakness in the daigou channel.

However, unlike a2 Milk, the sales of these products inside China haven't been strong, with Chinese Singles' Day sales falling well short of expectations.

Global Therapeutics acquisition.

In addition to this, the company revealed that the Global Therapeutics acquisition from Blackmores Limited (ASX: BKL) completed successfully on 30 November and its integration is progressing smoothly.

Management believes that this reflects the professional, collaborative approach of Global Therapeutics, McPherson's, and Blackmores.

McPherson's new Chief Executive Officer and Managing Director, Grant Peck, commented: "McPherson's year to date domestic sales growth reflects the consumer appeal of our market leading brands and our focus on new product innovation. All of the early signs are positive as we integrate Global Therapeutics into McPherson's and realise the complementary capabilities of the combined teams. Domestically, we continue to drive cashflow to support our mature dividend profile and modest debt levels."

Mr Peck, who was appointed CEO earlier this month after the sudden departure of Laurie McAllister following a series of terrible updates, also provided the market with guidance for the first half of FY 2021.

He revealed that McPherson's is on track to achieve its previous first half underlying profit before tax guidance in the range of $6.5 million to $7.5 million. This represents an 11.8% to 23.5% decline on the prior corresponding period's profit before tax of $8.5 million.

In addition to this, the new chief executive revealed that shareholders should expect a dividend March. He advised that the company's dividend policy is to pay a minimum dividend of 60% of underlying profit after tax, subject to cash requirements.

In line with this policy and based on its forecast first half underlying earnings, an interim fully franked dividend of at least 3 cents per share is expected to be paid to shareholders in March.

Annualised, this represents a fully franked 4.5% dividend yield. This may be far better than many had expected after its recent updates and guidance withdrawal.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended A2 Milk and Blackmores Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A panel of four judges hold up cards all showing the perfect score of ten out of ten
Share Market News

Here are the top 10 ASX 200 shares today

The ASX was back to fine form this Thursday...

Read more »

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Energy Shares

Top broker says Boss Energy shares have 29% upside

Nuclear energy continues to be an emerging theme for investors.

Read more »

A man looks down with fright as he falls towards the ground.
Share Fallers

Why 29Metals, Guzman Y Gomez, Mesoblast, and Pilbara Minerals shares are falling today

These shares are having a tough time on Thursday. What's going on?

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why Bravura, HMC, Magellan, and Perseus shares are pushing higher today

These shares are having a good session on Thursday. But why?

Read more »

Three young people lie in the surf on a beach wearing santa hats.
Share Market News

Will ASX 200 investors be gifted with a 'Santa rally'?

After a strong run in 2024, can the Santa rally send the ASX 200 to new records?

Read more »

A businessman stacks building blocks.
Technology Shares

Why has this ASX 200 tech stock rocketed 38% in a month?

The stars aligned for this stock over the past month.

Read more »

Three rockets heading to space
Share Gainers

3 ASX biotech shares rocketing 10% to 26% on BIG news!

Investors are sending these three ASX biotech stocks flying higher on Thursday.

Read more »

Broker looking at the share price.
Broker Notes

Here's the latest broker upgrades on ASX All Ords shares

Let's dive in.

Read more »